ABAndreas Bender

Andreas Bender

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Bender has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Dmitri Mikhailov

    Center for Proteomic Chemistry, Lead Discovery Informatics, Developmental and Molecular Pathways, and Global Discovery Chemistry, Chemogenetics and Proteomics, Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

    2 shared publications
  • Jeremy L. Jenkins

    Novartis Biomedical Research, Cambridge, MA, USA

    2 shared publications
  • Josef Scheiber

    Institute of Medicinal and Pharmaceutical Chemistry, University of Technology Braunschweig , Beethovenstrasse 55, D 38106 Braunschweig, Germany

    2 shared publications
  • Adriaan P. Ijzerman

    Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research (LACDR), Gorlaeus Laboratories, Leiden University, P.O. Box: 9502, 2300 RA Leiden (The Netherlands), Fax: (+31) 71‐527‐4576

    1 shared publication
  • Adriaan P. Ijzerman

    Leiden University Leiden The Netherlands

    1 shared publication
  • Dejan Bojanic

    1 shared publication

Latest Publications

  • Open Access

    A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization

    by Eelke van der Horst, Julio E Peironcely, Adriaan P Ijzerman, Margot W Beukers, Jonathan R Lane, Herman Wt van Vlijmen, Michael Tm Emmerich, Yasushi Okuno, Andreas Bender

    Background: G protein-coupled receptors (GPCRs) represent a family of well-characterized drug targets with significant therapeutic value. Phylogenetic classifications may help to understand the characteristics of individual GPCRs and their subtypes. Previous phylogenetic classifications were all based on the sequences of receptors, adding only minor information about the ligand binding properties of the receptors. In this work, we compare a sequence-based classification of receptors to a ligand-based classification of the same group of receptors, and evaluate the potential to use sequence relatedness as a predictor for ligand interactions thus aiding the quest for ligands of orphan receptors. Results: We present a classification of GPCRs that is purely based on their ligands, complementing sequence-based phylogenetic classifications of these receptors. Targets were hierarchically classified into phylogenetic trees, for both sequence space and ligand (substructure) space. The overall organization of the sequence-based tree and substructure-based tree was similar; in particular, the adenosine receptors cluster together as well as most peptide receptor subtypes (e.g. opioid, somatostatin) and adrenoceptor subtypes. In ligand space, the prostanoid and cannabinoid receptors are more distant from the other targets, whereas the tachykinin receptors, the oxytocin receptor, and serotonin receptors are closer to the other targets, which is indicative for ligand promiscuity. In 93% of the receptors studied, de-orphanization of a simulated orphan receptor using the ligands of related receptors performed better than random (AUC > 0.5) and for 35% of receptors de-orphanization performance was good (AUC > 0.7). Conclusions: We constructed a phylogenetic classification of GPCRs that is solely based on the ligands of these receptors. The similarities and differences with traditional sequence-based classifications were investigated: our ligand-based classification uncovers relationships among GPCRs that are not apparent from the sequence-based classification. This will shed light on potential cross-reactivity of GPCR ligands and will aid the design of new ligands with the desired activity profiles. In addition, we linked the ligand-based classification with a ligand-focused sequence-based classification described in literature and proved the potential of this method for de-orphanization of GPCRs.


  • Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases

    by Munikumar R. Doddareddy, Elisabeth C. Klaasse, Shagufta, Adriaan P. Ijzerman, Andreas Bender

    Ligand‐based in silico hERG models were generated for 2 644 compounds using linear discriminant analysis (LDA) and support vector machines (SVM). As a result, the dataset used for the model generation is the largest publicly available (see Supporting Information). Extended connectivity fingerprints (ECFPs) and functional class fingerprints (FCFPs) were used to describe chemical space. All models showed area under curve (AUC) values ranging from 0.89 to 0.94 in a fivefold cross‐validation, indicating high model consistency. Models correctly predicted 80 % of an additional, external test set; Y‐scrambling was also performed to rule out chance correlation. Additionally models based on patch clamp data and radioligand binding data were generated separately to analyze their predictive ability when compared to combined models. To experimentally validate the models, 50 of the predicted hERG blockers from the Chembridge database and ten of the predicted non‐hERG blockers from an in‐house compound library were selected for biological evaluation. Out of those 50 predicted hERG blockers, tested at a concentration of 10 μM, 18 compounds showed more than 50 % displacement of [3H]astemizole binding to cell membranes expressing the hERG channel. Ki values of four of the selected binders were determined to be in the micromolar and high nanomolar range (Ki (VH01)=2.0 μM, Ki (VH06)=0.15 μM, Ki (VH19)=1.1 μM and Ki (VH47)=18 μM). Of these four compounds, VH01 and VH47 showed also a second, even higher affinity binding site with Ki values of 7.4 nM and 36 nM, respectively. In the case of non‐hERG blockers, all ten compounds tested were found to be inactive, showing less than 50 % displacement of [3H]astemizole binding at 10 μM. These experimentally validated models were then used to virtually screen commercial compound databases to evaluate whether they contain hERG blockers. 109 784 (23 %) of Chembridge, 133 175 (38 %) of Chemdiv, 111 737 (31 %) of Asinex and 11 116 (18 %) of the Maybridge database were predicted to be hERG blockers by at least two of the models, a prediction which could, for example, be used as a pre‐filtering tool for compounds with potential hERG liabilities.


  • Use of Ligand Based Models for Protein Domains To Predict Novel Molecular Targets and Applications To Triage Affinity Chromatography Data

    by Andreas Bender, Dmitri Mikhailov, Meir Glick, Josef Scheiber, John W. Davies, Stephen Cleaver, Stephen Marshall, John A. Tallarico, Edmund Harrington, Ivan Cornella-Taracido, et al.

    The elucidation of drug targets is important both to optimize desired compound action and to understand drug side-effects. In this study, we created statistical models which link chemical substructures of ligands to protein domains in a probabilistic manner and employ the model to triage the results of affinity chromatography experiments. By annotating targets with their InterPro domains, general rules of ligand−protein domain associations were derived and successfully employed to predict protein targets outside the scope of the training set. This methodology was then tested on a proteomics affinity chromatography data set containing 699 compounds. The domain prediction model correctly detected 31.6% of the experimental targets at a specificity of 46.8%. This is striking since 86% of the predicted targets are not part of them (but share InterPro domains with them), and thus could not have been predicted by conventional target prediction approaches. Target predictions improve drastically when significance (FDR) scores for target pulldowns are employed, emphasizing their importance for eliminating artifacts. Filament proteins (such as actin and tubulin) are detected to be ‘frequent hitters’ in proteomics experiments and their presence in pulldowns is not supported by the target predictions. On the other hand, membrane-bound receptors such as serotonin and dopamine receptors are noticeably absent in the affinity chromatography sets, although their presence would be expected from the predicted targets of compounds. While this can partly be explained by the experimental setup, we suggest the computational methods employed here as a complementary step of identifying protein targets of small molecules. Affinity chromatography results for gefitinib are discussed in detail and while two out of the three kinases with the highest affinity to gefitinib in biochemical assays are detected by affinity chromatography, also the possible involvement of NSF as a target for modulating cancer progressions via beta-arrestin can be proposed by this method.


    • 1 May 2008
      • Vol. 11  (3) , 327-37

    Which aspects of HTS are empirically correlated with downstream success?

    by Andreas Bender, Dejan Bojanic, John W Davies, Thomas J Crisman, Dmitri Mikhailov, Josef Scheiber, Jeremy L Jenkins, Zhan Deng, W Adam G Hill, Maxim Popov, et al.

    High-throughput screening (HTS) is a well-established hit-finding approach used in the pharmaceutical industry. In this article, recent experience at Novartis with respect to factors influencing the success of HTS campaigns is discussed. An inherent measure of HTS quality could be defined by the assay Z and Z' factors, the number of hits and their biological potencies; however, such measures of quality do not always correlate with the advancement of hits to the later stages of drug discovery. Also, for many target classes, such as kinases, it is easy to identify hits, but, as a result of selectivity, intellectual property and other issues, the projects do not result in lead declarations. In this article, HTS success is defined as the fraction of HTS campaigns that advance into the later stages of drug discovery, and the major influencing factors are examined. Interestingly, screening compounds in individual wells or in mixtures did not have a major impact on the HTS success and, equally interesting, there was no difference in the progression rates of biochemical and cell-based assays. Particular target types, assay technologies, structure-activity relationships and powder availability had a much greater impact on success as defined above. In addition, significant mutual dependencies can be observed - while one assay format works well with one target type, this situation might be completely reversed for a combination of the same readout technology with a different target type. The results and opinions presented here should be regarded as groundwork, and a plethora of factors that influence the fate of a project, such as biophysical measurements, chemical attractiveness of the hits, strategic reasons and safety pharmacology, are not covered here. Nonetheless, it is hoped that this information will be used industry-wide to improve success rates in terms of hits progressing into exploratory chemistry and beyond. The support that can be obtained from new in silico approaches to phase transitions are also described, along with the gaps they are designed to fill.